Global Heparin Market to Surpass US$ 14 Billion by 2026 – Coherent Market Insights

SEATTLE--(BUSINESS WIRE)-- According to Coherent Market Insights, the global heparin market was valued at US$ 9.4 billion in 2017, and is projected to exhibit a CAGR of 5.1% over the forecast period (2018 – 2026).

Key Trends and Analysis of the Heparin Market:

Market players are focusing on product approvals and launches, which is expected to be a major factor for growth of global heparin market in the near future. For instance, in December 2017, Mylan N.V., a pharmaceutical company, received approval from the U.S. FDA for its abbreviated new drug applications (ANDAs) for Heparin Sodium Injection USP, 1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, and 20,000 USP/mL, all of which are packaged in multi-dose vials.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2602

Furthermore, in April, 2019, B. Braun Medical Inc. launched Heparin Sodium Injection, USP - 5,000 USP Unit / 0.5 mL prefilled syringe. The syringe is attached with safety needle for subcutaneous and intravenous use in the U.S.

Furthermore, in June 2018, Amphastar Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval of the company’s abbreviated new drug application (ANDA) supplement for semi-purified heparin and Heparin sodium USP.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/heparin-market-2602

Key Market Takeaways:

• The global heparin market is expected to exhibit a CAGR of 5.1% during the forecast period (2018–2026), attributed to rising cases of conditions such as coronary heart disease, pulmonary embolism, and deep vein thrombosis. Myocardial infarction (MI) is one of the major complications of coronary heart disease.
• According to the American Heart Association 2018 report, coronary heart disease is the leading cause (43.8%) of deaths due to cardiovascular disease in the U.S., followed by stroke (16.8%). As per the Centers for Disease Control and Prevention (CDC) 2015 report, deep vein thrombosis affected around 900,000 individuals in the U.S. annually.
• Asia Pacific heparin market is expected to grow at the highest rate during the forecast period, owing to increasing incidence of myocardial infarction (MI) among regional population. According to a study published by National Center for Biotechnology Information (NCBI) in 2015, Asian population is more susceptible to MI than white people. There are 50% higher cases of MI in South Asians than in white people in the U.K.
• Key players operating in the global heparin market include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.

Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2602

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005321/en/